Table 2.
Normalized Spike and Adenoviral Protein Expression
| Pre-vaccination serum 1:50 | Post-vaccination serum 1:50 | |||||||
|---|---|---|---|---|---|---|---|---|
| Ad26.COV2.S | ChAdOx1.S | Ad26.COV2.S | ChAdOx1.S | |||||
| Spike | Adeno | Spike | Adeno | Spike | Adeno | Spike | Adeno | |
| #1 (R) | 99% | 96% | 98% | 96% | 24% | 10% | 98% | 98% |
| #2 (R) | 96% | 95% | 98% | 97% | 96% | 94% | 99% | 99% |
| #3 (R) | 95% | 94% | 101% | 99% | 36% | 29% | 97% | 98% |
| #4 (R) | 98% | 97% | 98% | 96% | 8% | 5% | 94% | 95% |
| #5 (R) | 94% | 92% | 96% | 99% | 16% | 10% | 95% | 98% |
| #16 (R) | 92% | 92% | 101% | 101% | 43% | 26% | 94% | 98% |
| #17 (R) | 95% | 94% | 94% | 98% | 74% | 58% | 91% | 96% |
| Mediana | 95 [94–98] | 94 [92–96] | 98 [96–101] | 98 [96–99] | 36 [20–59] | 26 [10–43] | 95 [94–96] | 98 [97–98] |
| #6 (LR) | 91% | 89% | 95% | 96% | 9% | 7% | 94% | 95% |
| #7 (LR) | 77% | 70% | 99% | 99% | 4% | 4% | 20% | 24% |
| #8 (LR) | 93% | 87% | 99% | 99% | 10% | 11% | 77% | 89% |
| #9 (LR) | 100% | 100% | 100% | 100% | 46% | 27% | 100% | 98% |
| #18 (LR) | 99% | 99% | 99% | 98% | 38% | 22% | 98% | 96% |
| Median | 93 [84–99] | 89 [79–99] | 99 [97–100] | 99 [97–99] | 10 [9–10] | 11 [7–11] | 94 [77–94] | 95 [89–95] |
| #10 (NR) | 38% | 18% | 99% | 99% | 27% | 13% | 100% | 99% |
| #11 (NR) | 70% | 56% | 88% | 88% | 28% | 17% | 94% | 98% |
| #12 (NR) | 82% | 72% | 93% | 93% | 13% | 7% | 93% | 93% |
| #13 (NR) | 93% | 93% | 101% | 100% | 18% | 14% | 98% | 97% |
| #14 (NR) | 98% | 94% | 99% | 97% | 35% | 18% | 94% | 84% |
| #15 (NR) | 46% | 45% | 93% | 95% | 20% | 14% | 94% | 97% |
| Median | 76 [44–95] | 64 [38–94] | 96 [92–100] | 96 [92–99] | 23 [19–27] | 14 [13–17] | 94 [94–94] | 97 [94–97] |
#1-#15 HIV-1-infected subjects, #16-#18: HIV-1-uninfected subjects. Plasma was used for pre-vaccination samples from patients #3, #8 and #15. All other samples were sera. aMedians with IQRs in brackets